Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer

NCT ID: NCT01368263

Last Updated: 2015-04-03

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 8 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-09-30
• Study Completion Date: 2013-05-31

Brief Summary

This phase II trial studies the impact of a presurgical endocrine therapy, consisting of goserelin with letrozole or anastrozole on the treatment of premenopausal patients with stage II-III estrogen receptor-positive (ER+) and human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Endocrine therapy reduces the amount of estrogen in the body. E+ breast cancer require estrogen, so lower levels of estrogen may slow or stop cell growth. Giving goserelin together with letrozole or anastrozole before surgery may enhance the effectiveness of, or eliminate the need for, chemotherapy

Conditions

Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Group 1 (Ki67 <10%, E2 <= 15 pg/ml)

Patients receive 1 cycle (28 days) of endocrine therapy consisting of goserelin acetate SC on day 1 and letrozole or anastrozole PO QD. Neoadjuvant treatment repeats every 28 days for a total of 16-18 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo the appropriate standard surgical procedure to remove the cancer. Recommendations for postsurgical treatment will be based on PEPI score and physician discretion.

Group Type: EXPERIMENTAL

goserelin acetate

Intervention Type: DRUG

Given SC

letrozole

Intervention Type: DRUG

Given PO

anastrozole

Intervention Type: DRUG

Given PO

Surgery

Intervention Type: PROCEDURE

Group 2 (Ki67 >= 10%, E2 <= 15 pg/ml)

Patients receive 1 cycle (28 days) of endocrine therapy consisting of goserelin acetate SC on day 1 and letrozole or anastrozole PO QD. Patients receive standard neoadjuvant chemotherapy in the absence of disease progression or unacceptable toxicity. Patients then undergo the appropriate standard surgical procedure to remove the cancer. Postsurgical treatment at physician discretion.

Group Type: EXPERIMENTAL

goserelin acetate

Intervention Type: DRUG

Given SC

letrozole

Intervention Type: DRUG

Given PO

anastrozole

Intervention Type: DRUG

Given PO

chemotherapy

Intervention Type: DRUG

Standard chemotherapy

Surgery

Intervention Type: PROCEDURE

Group 3 (E2 > 15 pg/ml)

Patients receive 1 cycle (28 days) of endocrine therapy consisting of goserelin acetate SC on day 1 and letrozole or anastrozole PO QD. Patients receive standard neoadjuvant therapy at the discretion of the physician. Patients then undergo the appropriate standard surgical procedure to remove the cancer. Postsurgical treatment at physician discretion.

Group Type: EXPERIMENTAL

goserelin acetate

Intervention Type: DRUG

Given SC

letrozole

Intervention Type: DRUG

Given PO

anastrozole

Intervention Type: DRUG

Given PO

chemotherapy

Intervention Type: DRUG

Standard chemotherapy

Surgery

Intervention Type: PROCEDURE

Interventions

goserelin acetate

Given SC

Intervention Type: DRUG

letrozole

Given PO

Intervention Type: DRUG

anastrozole

Given PO

Intervention Type: DRUG

chemotherapy

Standard chemotherapy

Intervention Type: DRUG

Surgery

Intervention Type: PROCEDURE

Other Intervention Names

ICI-118630; ZDX; Zoladex; CGS 20267; Femara; LTZ; ANAS; Arimidex; ICI-D1033; chemo

Eligibility Criteria

Inclusion Criteria

• Patient must have histological or cytological confirmed invasive breast cancer
• Patient must be premenopausal confirmed by serum estradiol level in the premenopausal range (> 25 pg/ml) at the beginning of the study; for women on oral contraceptives, these agents must be held for two weeks before the estradiol assessment is made
• Patient must have a negative serum pregnancy test within 7 days of registration
• Patient's tumor must be ER+ with or without concomitant progesterone receptor-positive (PR+) with an Allred score of 6, 7 or 8; patients with > 66.6% of cells staining positive by conventional immunohistochemistry (IHC) have a minimum Allred score of 6 and are eligible
• Patient's tumors must be HER2 negative by local laboratory assessment: HER2 IHC 0, 1+, or 2+ with subsequent negative fluorescent in situ hybridization (FISH) (ratio < 1.8); negative FISH alone in absence of IHC is acceptable
• Patient must have T2-T4c, any N, M0 breast cancer, by clinical staging (physical examination)
• Patient's primary tumor must be palpable and measure > 2 cm by tape, ruler or caliper measurements in at least one dimension
• Patient must have mammogram and ultrasound of the breast within 42 days prior to registration; if a patient has clinically palpable or suspicious nodes, then an ultrasound of the axilla is also required
• Patient, as documented by the treating physician, must be clinically staged as one of the following:

• T4 a-c for which modified radical mastectomy with negative margins is the goal
• T2 or T3 for which conversion from needing mastectomy to breast conservation is the goal
• T2 for which lumpectomy at first attempt is the goal
• Patient must be > or = 18 years old.
• Patient must stop taking all forms of hormonal treatment, including oral or other form of hormonal contraceptive methods and all forms of hormone replacement therapy, at least two weeks prior to starting protocol therapy
• Patient must agree to use a "highly-effective form of non-hormonal contraception" (applies to patient and/or partner)
• Patient must be willing to undergo oophorectomy, if indicated
• Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of =< 2
• Patient must have normal organ and marrow function as defined below:
• Leukocytes >= 3,000/mcL
• Absolute neutrophil count >= 1,500/mcL
• Platelets >= 100,000/mcL
• Total bilirubin within normal institutional limits
• Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) =< 3.0 X institutional upper limit of normal (ULN)
• Creatinine within normal institutional limits OR
• Creatinine clearance >= 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal
• If the patient is a cancer survivor, all of the following criteria must be met
• Patient has undergone potentially curative therapy from all prior malignancies
• Patient must have no evidence of any prior malignancies for at least 5 years with no evidence of recurrence (except for successfully treated cervical carcinoma in situ, lobular carcinoma in situ of the breast, contralateral ductal carcinoma in situ (DCIS) treated with mastectomy or lumpectomy and radiation but without tamoxifen treatment, or non-melanoma skin cancer with no evidence of recurrence)
• Patient must be deemed by her treating physician to be at low risk (< 30%) for recurrence from prior malignancies
• Patient must be able to understand and willing to sign a written informed consent document

Exclusion Criteria

• Patient must not have inflammatory breast cancer defined as clinically significant erythema of the breast and/or documented dermal lymphatic invasion (not direct skin invasion by tumor or peau d'orange without erythema)
• Patient must not have had prior treatment for invasive breast cancer, including radiation, endocrine therapy, chemotherapy, or investigational agent; patients whose diagnosis was established by incision biopsy are not eligible
• Patient must not have had prior DCIS in the ipsilateral breast
• Patient must not have used tamoxifen for prior contralateral DCIS
• Patient must not have any evidence of distant metastasis (M1) on imaging; staging scans are not mandatory but any exams performed as standard of care throughout the study period will be collected for correlation as needed
• If patient does not agree to undergo mastectomy or lumpectomy after neoadjuvant therapy, she is ineligible for this study
• Patient must not be receiving other investigational agents or be enrolled in another neoadjuvant clinical trial for treatment of the existing breast cancer
• Pregnant and/or breastfeeding women are excluded from this study
• Patient must not have any concurrent life threatening illnesses
• Patient must not have undergone prior sentinel lymph node surgery; cores or FNA of lymph node are acceptable

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

National Cancer Institute (NCI)

NIH

Sponsor Role: collaborator

Washington University School of Medicine

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Timothy Pluard, M.D.

Role: PRINCIPAL_INVESTIGATOR

Washington University School of Medicine

Locations

Washington University School of Medicine

St Louis, Missouri, United States

Countries

United States

Related Links

http://www.siteman.wustl.edu

Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

Other Identifiers

201106141

Identifier Type: -

Identifier Source: org_study_id